NASDAQ: APYXApyx Medical Corp Stock
$1.38+0.06 (+4.55%)
Updated Apr 18, 2024
APYX Price
$1.38
Fair Value Price
N/A
Market Cap
$47.81M
52 Week Low
$1.21
52 Week High
$7.97
P/E
-2.56x
P/B
1.79x
P/S
1.73x
PEG
N/A
Dividend Yield
N/A
Revenue
$52.35M
Earnings
-$18.71M
Gross Margin
64.5%
Operating Margin
-35.66%
Profit Margin
-35.7%
Debt to Equity
1.96
Operating Cash Flow
-$5M
Beta
1.24
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
APYX Overview
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APYX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APYX is good value based on its book value relative to its share price (1.79x), compared to the US Medical Devices industry average (3.63x)
P/B vs Industry Valuation
APYX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APYX due diligence checks available for Premium users.
Be the first to know about important APYX news, forecast changes, insider trades & much more!
APYX News
Valuation
APYX fair value
Fair Value of APYX stock based on Discounted Cash Flow (DCF)
Price
$1.38
Fair Value
$2.64
Undervalued by
47.75%
APYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.56x
Industry
28.61x
Market
41.33x
APYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.79x
Industry
3.63x
APYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APYX's financial health
Profit margin
Revenue
$14.7M
Net Income
-$9.6M
Profit Margin
-65.5%
APYX's Earnings (EBIT) of -$18.67M... subscribe to Premium to read more.
Interest Coverage Financials
APYX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$79.2M
Liabilities
$52.3M
Debt to equity
1.96
APYX's short-term assets ($70.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APYX's short-term assets ($70.36M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APYX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
-$93.0k
Financing
$23.8M
APYX's operating cash flow (-$5.25M)... subscribe to Premium to read more.
Debt Coverage Financials
APYX vs Medical Device Stocks
Apyx Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.